Source: Atherosclerosis Supplements. Conference titles: International Symposium on Atherosclerosis. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA (TERAPIA), COLESTEROL, RESUMOS (EVENTOS)
ABNT
NUNES, V. S. et al. Ezetimibe plus sinvastatin treatment reduces fasting and potprandial remnant-like protein cholesterol in primary hypercholesterolemic patients. Atherosclerosis Supplements. Amsterdan: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 16 nov. 2024. , 2006APA
Nunes, V. S., Quintão, E. C. R., Neves, M. Q., Katona, K. N., Nakano, T., Nakajima, K., et al. (2006). Ezetimibe plus sinvastatin treatment reduces fasting and potprandial remnant-like protein cholesterol in primary hypercholesterolemic patients. Atherosclerosis Supplements. Amsterdan: Faculdade de Medicina, Universidade de São Paulo.NLM
Nunes VS, Quintão ECR, Neves MQ, Katona KN, Nakano T, Nakajima K, Nakandakare ER, Carvalho MDT, Souza HP de. Ezetimibe plus sinvastatin treatment reduces fasting and potprandial remnant-like protein cholesterol in primary hypercholesterolemic patients. Atherosclerosis Supplements. 2006 ; 7( 3): 548.[citado 2024 nov. 16 ]Vancouver
Nunes VS, Quintão ECR, Neves MQ, Katona KN, Nakano T, Nakajima K, Nakandakare ER, Carvalho MDT, Souza HP de. Ezetimibe plus sinvastatin treatment reduces fasting and potprandial remnant-like protein cholesterol in primary hypercholesterolemic patients. Atherosclerosis Supplements. 2006 ; 7( 3): 548.[citado 2024 nov. 16 ]